2021年与2020年美国儿童COVID-19或儿童多系统炎症综合征住院患者中严重神经系统受累分布的变化
该病例系列研究纳入2020年12月15日至2021年12月31日美国55家医院报告的2168例SARS-CoV-2相关疾病住院儿童和青少年,22%有神经系统受累,9%出现危及生命的神经系统疾病,其中多数疫苗符合条件者未接种疫苗。
要点
- 2168例住院患儿中476例(22%)有神经系统受累,其中42例(9%)出现危及生命的神经系统疾病。
- 危及生命的神经系统疾病包括中枢神经系统感染/脱髓鞘23例、卒中11例、严重脑病5例、急性暴发性脑水肿2例、吉兰-巴雷综合征1例。
- 42例危及生命者中10例(24%)出院时遗留新发神经功能缺损,8例(19%)死亡;16例疫苗符合条件者中15例(94%)未接种疫苗。
核心结论
- 2021年美国因COVID-19或MIS-C住院的儿童和青少年中SARS-CoV-2相关神经系统受累持续存在,且大多为一过性。
- 中枢神经系统感染/脱髓鞘在危及生命的疾病中占较高比例,大多数疫苗符合条件患者未接种疫苗。
- COVID-19疫苗接种可能预防部分SARS-CoV-2相关神经系统并发症,值得进一步研究。
研究设计与样本
- 病例系列研究,纳入2020年12月15日至2021年12月31日美国31个州55家医院报告至公共卫生监测系统的住院患者。
- 调查期间共入组2253例患者,排除85例疑似MIS-C但不符合标准者,最终分析2168例年龄<21岁、SARS-CoV-2检测阳性且符合MIS-C或急性COVID-19标准的患者。
- 随访至出院,由专家根据临床和/或神经影像学特征判定危及生命的神经系统受累。
主要发现
- 2168例纳入患者中58%为男性,中位年龄10.3岁;1435例(66%)符合MIS-C标准,476例(22%)有记录的神经系统受累。
- 有神经系统受累者较无受累者年龄更大(中位年龄12岁 vs 10岁),且更常有基础神经系统疾病(107/476[22%] vs 240/1692[14%])。
- 476例有神经系统受累者中42例(9%)出现急性SARS-CoV-2相关危及生命疾病:中枢神经系统感染/脱髓鞘23例(15例可能/确诊脑炎,6例脑膜炎,1例横贯性脊髓炎,1例非出血性白质脑病)、卒中11例、严重脑病5例、急性暴发性脑水肿2例、吉兰-巴雷综合征1例。
- 42例危及生命者中10例(24%)出院时存活但遗留新发神经功能缺损,8例(19%)死亡;16例疫苗符合条件者中15例(94%)未接种疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In 2020 during the COVID-19 pandemic, neurologic involvement was common in children and adolescents hospitalized in the United States for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related complications. OBJECTIVE: To provide an update on the spectrum of SARS-CoV-2-related neurologic involvement among children and adolescents in 2021. DESIGN, SETTING, AND PARTICIPANTS: Case series investigation of patients reported to public health surveillance hospitalized with SARS-CoV-2-related illness between December 15, 2020, and December 31, 2021, in 55 US hospitals in 31 states with follow-up at hospital discharge. A total of 2253 patients were enrolled during the investigation period. Patients suspected of having multisystem inflammatory syndrome in children (MIS-C) who did not meet criteria (n = 85) were excluded. Patients (<21 years) with positive SARS-CoV-2 test results (reverse transcriptase-polymerase chain reaction and/or antibody) meeting criteria for MIS-C or acute COVID-19 were included in the analysis. EXPOSURE: SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Patients with neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation or during hospitalization. Life-threatening neurologic involvement was adjudicated by experts based on clinical and/or neuroradiological features. Type and severity of neurologic involvement, laboratory and imaging data, vaccination status, and hospital discharge outcomes (death or survival with new neurologic deficits). RESULTS: Of 2168 patients included (58% male; median age, 10.3 years), 1435 (66%) met criteria for MIS-C, and 476 (22%) had documented neurologic involvement. Patients with neurologic involvement vs without were older (median age, 12 vs 10 years) and more frequently had underlying neurologic disorders (107 of 476 [22%] vs 240 of 1692 [14%]). Among those with neurologic involvement, 42 (9%) developed acute SARS-CoV-2-related life-threatening conditions, including central nervous system infection/demyelination (n = 23; 15 with possible/confirmed encephalitis, 6 meningitis, 1 transverse myelitis, 1 nonhemorrhagic leukoencephalopathy), stroke (n = 11), severe encephalopathy (n = 5), acute fulminant cerebral edema (n = 2), and Guillain-Barré syndrome (n = 1). Ten of 42 (24%) survived with new neurologic deficits at discharge and 8 (19%) died. Among patients with life-threatening neurologic conditions, 15 of 16 vaccine-eligible patients (94%) were unvaccinated. CONCLUSIONS AND RELEVANCE: SARS-CoV-2-related neurologic involvement persisted in US children and adolescents hospitalized for COVID-19 or MIS-C in 2021 and was again mostly transient. Central nervous system infection/demyelination accounted for a higher proportion of life-threatening conditions, and most vaccine-eligible patients were unvaccinated. COVID-19 vaccination may prevent some SARS-CoV-2-related neurologic complications and merits further study.
引用
- LaRovere KL, Poussaint TY, Young CC, et al. Changes in Distribution of Severe Neurologic Involvement in US Pediatric Inpatients With COVID-19 or Multisystem Inflammatory Syndrome in Children in 2021 vs 2020. JAMA Neurol. 2023. PMID: 36342679. doi:10.1001/jamaneurol.2022.3881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。